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Vpr is one of the auxiliary gene products encoded by HIV-1 genome. Vpr is a 14-kDa protein and exhibits several interesting
characteristics including incorporation into virus particles, oligomerization, localization in the nucleus, and positive regulation
of virus replication in primary cells. In an effort to define the structure–function relationship of Vpr, the role of the C-
terminus of Vpr was investigated. Site-specific mutagenesis involving deletion, insertion, and substitution of residues at the
C-terminus was utilized to generate variants of Vpr. Mutations introduced at the C-terminus affected properties of Vpr in
different ways: (i) Vpr containing amino acids 1–72 showed the virion incorporation phenotype, indicating that the C-terminus
is not essential for this function, (ii) the C-terminus contributes to the stability of Vpr, and (iii) substitution mutagenesis
involving the basic residues showed stability similar to that of wild type, indicating the lack of involvement of these residues
in this biochemical property of Vpr. The data generated in this study and our early mutagenic analyses on Vpr suggest that
domains noncontiguous in primary sequence contribute to the stability of Vpr through overall conformation of the protein.
q 1995 Academic Press, Inc.
HIV and other members of the lentivirus family of re- induction of disease by SIV in rhesus macaques, there
is no information available regarding the role of Vpr introviruses encode several nonstructural genes collec-
tively known as auxiliary or accessory genes (10, 22, 35). early infection and/or progression of HIV-1-associated
diseases.These include vif, vpr, tat, rev, vpu, and nef. Of all the
accessory gene products synthesized in infected cells, Besides its association with the virus particle, Vpr ex-
hibits several interesting characteristics. These includeVpr has the property of getting incorporated into HIV-1
particles during virus morphogenesis as do both Vpr and nuclear localization (23, 27, 42), oligomerization (4, 32,
Vpx of HIV-2, which get incorporated into HIV-2 particles 43), ability to turn cells into differentiation pathway (20),
(8, 41). Vpr is highly conserved among HIV-1 and HIV-2/ ability to arrest cells in cell cycle progression (33), and
SIV and it was speculated that the conserved nature of affinity for cellular proteins (42). At the biological level,
the gene may have important functional implications for Vpr is known to have a minimal effect in primary lymphoid
the life cycle of HIV-1 (10, 12, 30). It was reported that cells and established cell lines, and it is needed for the
an intact vpr is essential for the development of the AIDS- productive HIV-1 infection of macrophages (2, 3, 11, 31,
like disease in rhesus macaques infected with SIV (17). 38). In support of this, Heinzinger and co-workers (14)
However, in a recent study, Gibbs and co-workers (13) showed that Vpr participates in the transport of preinte-
showed that rhesus macaques inoculated with SIVmac gration complexes from the cytoplasm to the nucleus. It
containing alterations in vpr and vpx progressed to AIDS has been reported that a nonfunctional Vpr is associated
in a manner similar to macaques infected with the wild- with the successful establishment of cells chronically
type virus. Based on these data, it was suggested that infected with HIV-1 either alone (33) or in combination
Vpr provided only a slight facilitating advantage for wild- with Nef (29). Vpr had also been shown to modulate the
type SIVmac replication in vivo. Further, utilizing neonatal expression of HIV-1 (7, 21). HIV-1 Vpr contains 96 amino
macaques, Baba and co-workers (1) noted pathogenicity acids and is conserved among all HIV-1 isolates (30, 36).
despite deletion of vpr and nef genes in SIV. While these Work from our laboratory involving secondary structure
studies indicate the nonessential nature of Vpr for the analysis and site-specific mutagenesis of the predicted
amino acid residues suggested that Vpr contains six pu-
tative domains. These include N-terminal domain (resi-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (215) 923-7144. dues 1–16), helical domain I (residues 17–34), loop re-
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FIG. 1. Schematic representation of mutant Vpr. Overlap extension polymerase chain reaction (PCR) (15) was used to introduce the site-specific
mutations into vpr derived from the macrophage-tropic molecular clone of HIV-1 89.6 (9). The primers used for the generation of Vpr mutants were
Vpr85 (0) 5* CCCCCTCGAGCTATTGAATAATGCCTAT 3*; Vpr76 (0) 5* CCCCCTCGAGCTAACACCCAATTCTGAA 3*; VprR87S (0) 5* CCCCCCTCG-
AGCTAGGATTTACTGGCTCCATTTCTTGTTCTGCTGTGTTGAAT 3*; VprK95A (0) 5* CCCCCCTCGAGCTAGGATGCACTGGCTCAATTTCTTG 3*; VprCB
(/) 5* ATAGGCATTATTCAACAGAGCAGCACAAGCAATGGAGCC 3*; VprCB (0) 5* CTGTTGAATAATGCCTATACTGCTATGACTACACCCAAT 3*
Vpr80Ins (/) 5* CGACATAGCAGAAGGCCCATAGGCATTATTCAACAC 3*; Vpr80Ins (0) 5* GGGCCTTCTGCTATGTCGACACCC 3*. The numbers indi-
cate the predicted amino acid residues of Vpr.
gion (residues 35–45), helical domain II (residues 46 – quences (QNWVST) and a termination codon (30). Stud-
ies carried out with this proviral DNA clone reported the74), conserved dipeptide motif (residues 75–76), and C-
terminal basic amino acid-rich domain (residues 77–96) detection of a lack of incorporation of appropriate-sized
Vpr in transfected cells (18). The second group of Vpr(26). Importantly, mutagenesis studies of helical domain I
showed that this domain is essential for stability, nuclear mutants contains an insertion of 2 amino acids in Vpr
coding sequences. Arg and Pro residues were insertedlocalization, and virion incorporation of Vpr (24, 25, 27).
Further, it was also reported that conserved glycine and between residues 80 and 81 of Vpr and the introduction
of proline was expected to disrupt the higher order pro-cysteine residues are not essential for virion incorpora-
tion of Vpr (26). However, mutation of the cysteine residue tein structure in this region. The third group consisted of
substitution mutants of Vpr. As pointed out earlier, theshowed an effect on the stability of the protein (26).
Regarding the structure–function relationship of Vpr, C-terminus of Vpr is rich in basic residues. To evaluate
the role of basic residues specifically, several substitu-there is very little known about the C-terminal domain.
Paxton and co-workers (32) reported that deletion of 12 tion mutants were generated. Mutant VprCB contains
substitutions at residues 77, 80, 87, 88, 90, and 95. Inamino acids from the C-terminus resulted in the elimina-
tion of Vpr incorporation into virus particles. On the other addition, we also used two substitution mutants in which
the basic residues R87 and K95 were exchanged withhand, Ratner and co-workers reported that deletion of 17
amino acids from the C-terminus reduced the level of serine and alanine, respectively. These mutants were
verified by DNA sequence analysis (34).Vpr incorporation into virus particles (37). In our effort to
define the functional domains of Vpr, we have targeted In order to assess the expression of Vpr mutants, we
initially characterized these clones in an in vitro transcrip-the C-terminal amino acid residues for analysis in this
study. Combinations of deletions, insertions, and substi- tion/translation system. In vitro-translated Vpr was immu-
noprecipitated with polyclonal Vpr antiserum. As ex-tution mutagenesis were utilized to address this. Our
results indicate that the C-terminus of Vpr contributes to pected, the wild-type Vpr showed a band of 14 kDa and
the C-terminal deletion mutants correspondingly re-the stability and is not essential for its incorporation into
the virus particle. vealed a reduction in size of Vpr (Fig. 2). To monitor the
expression of Vpr in cells, we employed the vacciniaTo generate vpr mutants, we have used pCDVpr, an
expression plasmid, in which Vpr coding sequences virus–T7 RNA polymerase-based expression system as
described. vTF7-3-infected HeLa cells were transfectedwere cloned between T7 promoter and bovine growth
hormone poly(A) signal sequences. Three groups of Vpr with wild-type or mutant Vpr expression plasmids by the
lipofectin method. Radioimmunoprecipitation analysis ofmutants were generated to evaluate the role of the C-
terminus of Vpr. The first group comprises C-terminal the extracts from cells transfected with wild-type Vpr
showed a protein of 14 kDa while the mock anddeletion mutants and the schematic diagram of the mu-
tants is shown in Fig. 1. The deletion constructs were pCDVprD-transfected cells (data not shown) failed to
show the corresponding protein (Fig. 3). As expected,generated by utilizing the appropriate primers containing
translation termination signal sequences. The constructs deletion constructs Vpr85 and Vpr76 directed the synthe-
sis of Vpr which was reduced in size. The protein en-contain deletions of amino acids progressively from the
C-terminus of Vpr. For these studies, we also utilized an coded by Vpr derived from HXB2 ran similar to Vpr76 in
SDS–PAGE.altered Vpr which is present in HXB2 proviral DNA. HXB2
Vpr has 72 amino acids followed by a frameshift leading To address the role of the C-terminus residues in incor-
poration of Vpr into virus-like particles directed by HIV-to an addition of 6 residues unrelated to Vpr coding se-
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FIG. 2. Expression of HIV-1 Vpr mutants in vitro. Wild-type and mutant
Vpr expression plasmids were used for coupled in vitro transcription/
translation according to the manufacturer’s instructions (Promega). Im-
munoprecipitation of the in vitro-translated proteins was performed with
Vpr antiserum as described previously (25). Immunoprecipitates were
analyzed by SDS–12% PAGE. The designation of the Vpr plasmids is
indicated at the top.
1 Gag, we transfected vTF7-3-infected HeLa cells with
the Gag expression plasmid (pCDGag) in combination
FIG. 4. Incorporation of Vpr into virus-like particles directed by Gag.
with wild-type or mutant Vpr expression plasmids. Immu- Cotransfection of pCDGag with wild-type or mutant Vpr expression
noprecipitation of Vpr and Gag was performed in cell plasmids was carried out using vTF7-3-infected HeLa cells as de-
scribed previously (12, 25). Transfected cells were labeled with 35S-culture supernatant using anti-Vpr antiserum and HIV-1
protein labeling mix for 5 hr, the culture medium was cleared by centrif-antiserum. Expression of Vpr alone did not result in the
ugation and concentrated using Centricon 30 concentrators, and virus-release of Vpr into the culture media. Coexpression of
like particles were resuspended with RIPA buffer. Immunoprecipitation
Gag and Vpr resulted in the export of Vpr into the culture was carried out using anti-HIV and anti-Vpr antiserum and analyzed
medium in association with virus-like particles. Cotrans- by SDS–12% PAGE. The electrophoretic positions of Gag and Vpr are
shown at the right and molecular mass markers are shown at the leftfection of mutant Vpr with Gag showed that C-terminal
in kilodaltons.deletion mutants retained the ability to get incorporated
into the virus particles (Fig. 4). Though wild-type and
Vpr85 registered an intense signal, mutants Vpr76 and
terminus of Vpr is not essential for the incorporation ofVprHXB2 showed a weaker signal of Vpr in virus particles
Vpr into the virus particles.than the wild-type. These results indicate that the C-
The presence of a reduced level of Vpr in virus parti-
cles in Vpr76- and VprHXB2-transfected cells prompted
us to analyze the stability of C-terminal-truncated Vpr in
cells. Vpr plasmids encoding wild-type or mutant vpr
were transfected into vTF7-3-infected HeLa cells and
pulse labeled for 30 min. After different chase periods,
cell lysates were immunoprecipitated with anti-Vpr anti-
body and subjected to SDS–12% PAGE. Wild-type Vpr
was stable in cells for the chase period of 24 hr used in
this study. However, the Vpr expressed by deletion mu-
tants showed altered stability in comparison to the wild-
type (Figs. 5A and 5B). Deletion of 11 amino acids from
the C-terminus (Vpr85) resulted in the reduced stability
of Vpr (approximately 60%) in comparison to wild type.
Interestingly, Vpr directed by mutants Vpr76 andFIG. 3. Expression of C-terminal Vpr mutants in HeLa cells. Recombi-
nant vaccinia virus (vTF7-3)-infected HeLa cells were transfected with VprHXB2 showed an altered stability with 10–30% of Vpr
wild-type and mutant Vpr expression plasmids (12). Transfected cells in comparison to wild-type at the end of the 24-hr chase
were labeled with 35S-protein labeling mix for 2 hr and the cell-associ- period (Fig. 5B). Also, Vpr directed by both Vpr76 and
ated Vpr proteins were immunoprecipitated with anti-Vpr antiserum as
VprHXB2 showed about 50% reduction by 3 hr. Thesedescribed previously (25). Immunoprecipitates were analyzed by SDS–
results suggest that the C-terminus may contribute to the12% PAGE. The designation of the Vpr plasmids is indicated at the
top. stability of Vpr. As pointed out earlier, the C-terminus of
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FIG. 5. Stability of C-terminal-truncated Vpr proteins. (A) Wild-type and mutant Vpr expression plasmids were transfected into the vTF7-3-infected
HeLa cells. Transfected cells were pulse-labeled for 30 min with 200 mCi of 35S-protein labeling mix and chased for different periods. Cells were
then lysed and the cell-associated Vpr protein was immunoprecipitated with anti-Vpr antiserum and analyzed by SDS–12% PAGE. Chase periods
are indicated at the top. (B) Stability of Vpr mutants by densitometric scanning analysis.
Vpr contains a cluster of basic amino acids (8/20). The that the basic amino acids replaced individually with ala-
nine or serine did not affect the virion incorporation func-basic amino acid residues have been implicated in con-
ferring stability to the protein. We have generated mutant tion of Vpr (24; unpublished data). The insertion mutant
which contains 2 additional amino acids between resi-Vpr containing substitutions involving basic amino acids;
Vpr directed by the substitution mutants showed expres- dues 80 and 81 of Vpr also showed incorporation similar
to that of wild-type Vpr. The Vpr constructs containingsion and stability similar to the wild type (data not shown).
The present study examined the role of C-terminal resi- deletions at the C-terminus provide interesting data with
respect to virion incorporation of Vpr. Deletions of 11 anddues of Vpr in stability and virion incorporation functions
of Vpr. The characteristic feature of this region of Vpr is 20 amino acid residues from the C-terminus resulted in
a protein that retained the virion incorporation propertythe presence of basic amino acid residues. Comparison
of HIV-1 Vpr and Vpr and Vpx of HIV-2 shows residues of Vpr. Also the virion incorporation phenotype was ob-
served for Vpr derived from a molecular clone designatedconserved only in the amino terminus and central region
and does not show homology at the C-terminus (30, 36). HXB2. The Vpr of this proviral clone contains a frameshift
mutation that adds 6 amino acids unrelated to Vpr afterThe secondary structure prediction by Chou and Fasman
(6) and Garnier and co-workers (5) indicates a b-sheet residue 72 followed by a termination codon at 79 (18).
The amino acids which replace the native residues ofstructure for the C-terminus of Vpr. Strikingly, the C-termi-
nus of Vpr resembles a portion of ribosomal protein Vpr between 73 and 78 (QNWVST) differ from wild-type
Vpr (30). Analysis of the virion incorporation function ofwhich has the potential to bind nucleic acids (40). The
role of the C-terminus in Vpr function was evaluated by Vpr with the deletion constructs further showed a re-
duced level of Vpr present in the virus particles. Theutilizing several mutagenesis approaches including dele-
tion, insertion, and substitution. The mutant Vpr con- reduction in the level of Vpr present in virus particles
may have resulted from the reduced synthesis of Vpr instructs directed the expression of proteins of identical
sizes both in vitro and in vivo. Utilizing cotransfection of cells, loss of epitopes present in the C-terminus region,
lower rate of incorporation, and/or altered rate of VprGag and Vpr encoding plasmids, it was also possible to
assess the virion incorporation property of Vpr (23, 24). degradation. In vitro synthesis of Vpr by a coupled tran-
scription/translation system showed equal amount of VprThe data generated with substitution mutations suggest
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